<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02245399</url>
  </required_header>
  <id_info>
    <org_study_id>REB# 14-086</org_study_id>
    <secondary_id>CFC/Fund 200134/496744</secondary_id>
    <nct_id>NCT02245399</nct_id>
  </id_info>
  <brief_title>Canola-Mediterranean Diet Study in T2DM</brief_title>
  <official_title>Canola Enriched Mediterranean Type Weight Loss Diet in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canola Council of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess whether a Mediterranean-type weight-loss diet, enriched
      with canola oil, high in plant protein, and low in carbohydrates will produce blood sugar
      control, reduce coronary heart disease (CHD) risk factors and maximize weight loss, better
      than conventional higher carbohydrate diets in overweight diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators plan to assess the effects of increasing both canola oil and plant protein
      foods while reducing carbohydrate intake in the context of a Mediterranean type diet on
      weight loss, glycemic control and cardiovascular risk factors in type 2 diabetes.

      Obesity rates in Western nations have shown a dramatic rise in the last 20 years and diabetes
      rates have doubled, a trend which is predicted to be repeated over the next 20 years. In
      Canada the predicted cost to the healthcare system in only 7 years will rise to $17 billion.
      Weight loss diets (such as Atkins, Eddies, South Beach and Zone) emphasizing carbohydrate
      restriction have become increasingly popular for the prevention and treatment of diabetes. As
      a result, lower carbohydrate diets are being selected by health conscious members of the
      general population including those with diabetes. Because such diets in effect promote a high
      intake of protein from animal sources, even in the presence of weight loss, serum cholesterol
      levels rise due to increased cholesterol and saturated fat intake; and a further rise in
      serum lipids is likely to occur in the long term when weight loss has ceased. On the other
      hand, lower carbohydrate dietary patterns that are higher in plant rather than animal fat and
      proteins have been associated with improved blood lipids and reduced risk of heart disease
      and type 2 diabetes.

      The investigators have therefore planned a study in which a weight reducing low carbohydrate,
      Mediterranean type diet that is high in plant proteins and canola oil will be compared to a
      weight reducing high cereal fibre diet in a 3 month study. 150 overweight and obese
      participants with type 2 diabetes will be randomized to one of 2 treatments.

      Study visits will be as follows: weeks -2, 0 (for randomization), 2, 4, 8, 10 and 12. Body
      measurements, blood pressure and blood samples will be taken at each visit except week 2. The
      week 2 visit will be mainly for reinforcement of dietary advice; also body weight will be
      measured and blood drawn for fast glucose and HbA1c. Diet records will be reviewed at all
      visits. 24 hour urine samples will be collected at week 0 and week 12.

      On completion of the 12 week study, participants will be given the option of continuing on
      the same diet or trying the opposite diet for a further 12 weeks. Visits will be every 4
      weeks for a total of 3 visit. Body measurements, blood pressure and blood samples will be
      taken during these visits as in the initial 12 week study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in HbA1c</measure>
    <time_frame>Measured at weeks -2, 0, and then at weeks 8, 10 and 12</time_frame>
    <description>The baseline HbA1c will be the average HbA1c of weeks -2 and week 0. The end HbA1c will be the average HbA1c of weeks 8, 10 and 12. Change will be the difference between the end and baseline values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>baseline (week 0) and end (week 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood glucose</measure>
    <time_frame>At weeks 0, 2, 4, 8, 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lipids: total cholesterol, LDL-chol, HDL-chol and Triglycerides</measure>
    <time_frame>At weeks 0, 4, 8, 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>At weeks 0, 4, 8, 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour Ambulatory blood pressure profile</measure>
    <time_frame>At weeks -1 and 12</time_frame>
    <description>Measurement will be done using a non-invasive SpaceLabs 90217 Ambulatory BP monitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diet history</measure>
    <time_frame>At weeks 0, 2, 4, 8, 10 and 12</time_frame>
    <description>7-day food records brought in at weeks 0, 2, 4, 8, 10 and 12 will be analyzed for macro and micro nutrient intakes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>At weeks 0 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol absorption</measure>
    <time_frame>At weeks -1 and 12</time_frame>
    <description>This is an optional sub-study that will be carried out prior to the first and last weeks of the 12 week study. On day 1 (a Monday) of the week -1 and last weeks of the study after an overnight 12hr fast, blood will be drawn and participants will be asked to ingest 75mg of the stable carbon isotope [3, 4-13C] cholesterol dissolved in 5g of margarine and spread on half of an English muffin. Subsequent blood draws will be taken after an overnight 12hr fast, at 48 h (a Wednesday) and 72 h (a Thursday) after ingestion of the labeled cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in LDL particle size</measure>
    <time_frame>Weeks 0 and 12</time_frame>
    <description>LDL particle size at weeks 0 and 12 will be determined by assessing their electrophoretic characteristics obtained by non-denaturing polyacrylamide gradient (2-16%) gel electrophoresis of serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary analyses</measure>
    <time_frame>week 0 and week 12</time_frame>
    <description>24 hr urine samples will be analyzed for creatinine, urea, C-peptide, minerals, electrolytes and other dietary biomarkers</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Satiety</measure>
    <time_frame>at weeks 0, 2, 4, 8, 10 and 12</time_frame>
    <description>Using a 9-point bipolar semantic scale where -4 is extremely hungry, 0 is neutral and +4 is uncomfortably full, participants will rate their overall feeling of satiety for the previous week.</description>
  </other_outcome>
  <other_outcome>
    <measure>Taste (palatability) of the study diets, breads and other supplements given</measure>
    <time_frame>At weeks 2, 4, 8, 10 and 12</time_frame>
    <description>Using a scale of 1 (strongly dislike) to 10 (like very much), participants will rate the taste (palatability) of the study diet and supplements including study breads, vegan 'meats' and egg products.</description>
  </other_outcome>
  <other_outcome>
    <measure>The Medical Outcomes Study 36-Item Short Form Questionnaire (SF-36)</measure>
    <time_frame>At weeks 0 and 12</time_frame>
    <description>Survey on quality of life</description>
  </other_outcome>
  <other_outcome>
    <measure>Genetic whole genome testing</measure>
    <time_frame>Week 0 or any other time point</time_frame>
    <description>One time sample collection of buffy coat (from white cells) for future study on gene, diet and chronic disease relationship.</description>
  </other_outcome>
  <other_outcome>
    <measure>complete blood count (CBC)</measure>
    <time_frame>Week 0 and week 12</time_frame>
    <description>Health check at start and end of study</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal function test</measure>
    <time_frame>week 0 and week 12</time_frame>
    <description>Health check at start and end of study</description>
  </other_outcome>
  <other_outcome>
    <measure>Liver function test</measure>
    <time_frame>week 0 and week 12</time_frame>
    <description>Health check at start and end of study</description>
  </other_outcome>
  <other_outcome>
    <measure>Prostatic specific antigen (PSA)</measure>
    <time_frame>week 0 and week 12</time_frame>
    <description>Male participants will undergo this test.</description>
  </other_outcome>
  <other_outcome>
    <measure>sustainability of diet</measure>
    <time_frame>week 10 and week 12</time_frame>
    <description>using a scale of 1 (study diet will be very difficult to sustain) to 10 (study diet will be very easy to sustain) participants will assess how sustainable their assigned diet will be on a long-term basis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Testosterone level</measure>
    <time_frame>week 0 and week 12</time_frame>
    <description>Male participants will undergo this test</description>
  </other_outcome>
  <other_outcome>
    <measure>Estradiol level</measure>
    <time_frame>week 0 and week 12</time_frame>
    <description>Female participants will undergo this test</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>A canola oil enriched mediterranean diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be advised to consume, a low-carbohydrate diet (26-32% of calories), high in vegetable protein (28-32%) and fat (41-45%) with canola as the major component (10%). Carbohydrate sources will feature viscous fiber-containing foods (including psyllium cereal, oats and barley) and low-starch vegetables (emphasizing okra and eggplant) for the relatively limited amount of carbohydrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A high wheat fiber diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participant will be advised to consume a high carbohydrate diet (58% carbohydrate, 16% protein and 25% fat) emphasizing whole wheat/whole grain cereals and increased high fiber alternatives, with fruits and vegetables.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>A canola oil enriched mediterranean diet</intervention_name>
    <description>The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A high protein canola oil-enriched test bread will be provided as a supplement.</description>
    <arm_group_label>A canola oil enriched mediterranean diet</arm_group_label>
    <other_name>A mediterranean weight-reducing diet emphasizing canola oil</other_name>
    <other_name>Eco-Atkins diet</other_name>
    <other_name>Low carbohydrate dietary portfolio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>A high wheat fiber diet</intervention_name>
    <description>The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A whole wheat control bread will be provided as a supplement to participants</description>
    <arm_group_label>A high wheat fiber diet</arm_group_label>
    <other_name>DASH-type diet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women with type 2 diabetes diagnosed for more than 6 months

          -  BMI &gt;27 (non-Asians); BMI &gt;25 (Asians)

          -  HbA1c between 6.5% and 8.5% at screening, and at the preparation visit before starting
             diet

          -  on a stable prescribed dose of oral diabetes medication for at least 2 months

          -  on a stable dose of lipid medication for at least 2 weeks, if prescribed

          -  on a stable dose of blood pressure medication for at least 1 week, if prescribed

          -  have a family physician

          -  can keep written food records, with the use of a digital scale

        Exclusion Criteria:

        Individuals with the following characteristics/conditions will be excluded

          -  on insulin

          -  on steroids

          -  on warfarin (Coumadin)

          -  GI disease (gastroparesis, celiac, colitis, Crohn's disease, Inflammatory Bowel
             Syndrome)

          -  history of cancer, except non-melanoma skin cancer (basal cell, squamous cell)

          -  major cardiovascular event (stroke, myocardial infarction) in past 6 months

          -  major surgery in past 6 months

          -  major debilitating disorder

          -  liver disease (AST or ALT&gt; 3x the upper limit of normal) except non-alcoholic fatty
             liver (NAFL) disease or non-alcoholic steatohepatitis (NASH).

          -  hepatitis B or C

          -  renal failure (creatinine &gt; 150 mmol/L)

          -  serum triglycerides &gt;4.5mmol/L

          -  acute or chronic infections (bacterial or viral)

          -  chronic inflammatory diseases (e.g. lupus, ulcerative colitis)

          -  blood pressure &gt;145/90, unless approved by their family physician

          -  alcohol consumption &gt;2 drinks/d

          -  food allergies to wheat, canola, or other study food components

          -  any condition determined by the investigators to make the subject unsuitable for the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Jenkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital / University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cyril Kendall, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vladimir Vuksan, PhD</last_name>
    <role>Study Director</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Jones, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benoit Lamarche, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3T 6C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Risk Factor Modification Centre, St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Nutraceuticals and Functional Foods, Laval University</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Alhassan S, Kim S, Bersamin A, King AC, Gardner CD. Dietary adherence and weight loss success among overweight women: results from the A TO Z weight loss study. Int J Obes (Lond). 2008 Jun;32(6):985-91. doi: 10.1038/ijo.2008.8. Epub 2008 Feb 12.</citation>
    <PMID>18268511</PMID>
  </reference>
  <reference>
    <citation>Anderson JW, Randles KM, Kendall CW, Jenkins DJ. Carbohydrate and fiber recommendations for individuals with diabetes: a quantitative assessment and meta-analysis of the evidence. J Am Coll Nutr. 2004 Feb;23(1):5-17. Review.</citation>
    <PMID>14963049</PMID>
  </reference>
  <reference>
    <citation>Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, Golan R, Fraser D, Bolotin A, Vardi H, Tangi-Rozental O, Zuk-Ramot R, Sarusi B, Brickner D, Schwartz Z, Sheiner E, Marko R, Katorza E, Thiery J, Fiedler GM, Bl√ºher M, Stumvoll M, Stampfer MJ; Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008 Jul 17;359(3):229-41. doi: 10.1056/NEJMoa0708681. Erratum in: N Engl J Med. 2009 Dec 31;361(27):2681.</citation>
    <PMID>18635428</PMID>
  </reference>
  <reference>
    <citation>Jenkins DJ, Wong JM, Kendall CW, Esfahani A, Ng VW, Leong TC, Faulkner DA, Vidgen E, Greaves KA, Paul G, Singer W. The effect of a plant-based low-carbohydrate (&quot;Eco-Atkins&quot;) diet on body weight and blood lipid concentrations in hyperlipidemic subjects. Arch Intern Med. 2009 Jun 8;169(11):1046-54. doi: 10.1001/archinternmed.2009.115. Erratum in: Arch Intern Med. 2009 Sep 14;169(16):1490.</citation>
    <PMID>19506174</PMID>
  </reference>
  <reference>
    <citation>Guariguata L, Whiting D, Weil C, Unwin N. The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults. Diabetes Res Clin Pract. 2011 Dec;94(3):322-32. doi: 10.1016/j.diabres.2011.10.040. Epub 2011 Nov 17.</citation>
    <PMID>22100977</PMID>
  </reference>
  <reference>
    <citation>Kris-Etherton P, Eckel RH, Howard BV, St Jeor S, Bazzarre TL; Nutrition Committee Population Science Committee and Clinical Science Committee of the American Heart Association. AHA Science Advisory: Lyon Diet Heart Study. Benefits of a Mediterranean-style, National Cholesterol Education Program/American Heart Association Step I Dietary Pattern on Cardiovascular Disease. Circulation. 2001 Apr 3;103(13):1823-5.</citation>
    <PMID>11282918</PMID>
  </reference>
  <reference>
    <citation>Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, McManus K, Champagne CM, Bishop LM, Laranjo N, Leboff MS, Rood JC, de Jonge L, Greenway FL, Loria CM, Obarzanek E, Williamson DA. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009 Feb 26;360(9):859-73. doi: 10.1056/NEJMoa0804748.</citation>
    <PMID>19246357</PMID>
  </reference>
  <reference>
    <citation>Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499-502.</citation>
    <PMID>4337382</PMID>
  </reference>
  <reference>
    <citation>Jenkins DJ, Wong JM, Kendall CW, Esfahani A, Ng VW, Leong TC, Faulkner DA, Vidgen E, Paul G, Mukherjea R, Krul ES, Singer W. Effect of a 6-month vegan low-carbohydrate ('Eco-Atkins') diet on cardiovascular risk factors and body weight in hyperlipidaemic adults: a randomised controlled trial. BMJ Open. 2014 Feb 5;4(2):e003505. doi: 10.1136/bmjopen-2013-003505.</citation>
    <PMID>24500611</PMID>
  </reference>
  <reference>
    <citation>Gremaud G, Piguet C, Baumgartner M, Pouteau E, Decarli B, Berger A, Fay LB. Simultaneous assessment of cholesterol absorption and synthesis in humans using on-line gas chromatography/ combustion and gas chromatography/pyrolysis/isotope-ratio mass spectrometry. Rapid Commun Mass Spectrom. 2001;15(14):1207-13.</citation>
    <PMID>11445904</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2014</study_first_submitted>
  <study_first_submitted_qc>September 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2014</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Weight loss</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Cardiovascular disease (CVD) risk</keyword>
  <keyword>Weight loss diet</keyword>
  <keyword>mediterranean type diet</keyword>
  <keyword>Canola oil</keyword>
  <keyword>Low-carbohydrate diet</keyword>
  <keyword>Glycemic index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

